Literature DB >> 12127862

Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors.

John Nemunaitis1, Casey Cunningham.   

Abstract

The treatment of cancer by genetic manipulation of either the tumor itself or the patient as a whole offers new avenues for the treatment of otherwise refractory cancers. Gene therapy seeks to correct underlying genetic defects in malignant tissue or to augment the host defense response or to promote selectivity of other therapies. Many innovative and exciting genetic targets have been recently identified. However, the field as a whole is still constrained by limitations of gene delivery. The most common vector for gene delivery is modified adenovirus. In this review, we survey a sampling of current therapeutic approaches that depend upon adenoviral delivery vehicles and outline the advantages and disadvantages of this vector system.

Entities:  

Mesh:

Year:  2002        PMID: 12127862     DOI: 10.1016/s1368-7646(02)00048-1

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  4 in total

1.  Conference report--gene therapy and lung cancer--no time to wait.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-07-16

2.  Characterization of the complete genome of the Tupaia (tree shrew) adenovirus.

Authors:  Eva Schöndorf; Udo Bahr; Michaela Handermann; Gholamreza Darai
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 3.  Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.

Authors:  Sandeep S Patil; Ivaylo Gentschev; Ingo Nolte; Gregory Ogilvie; Aladar A Szalay
Journal:  J Transl Med       Date:  2012-01-04       Impact factor: 5.531

Review 4.  Oncolytic virotherapy of canine and feline cancer.

Authors:  Ivaylo Gentschev; Sandeep S Patil; Ivan Petrov; Joseph Cappello; Marion Adelfinger; Aladar A Szalay
Journal:  Viruses       Date:  2014-05-16       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.